ORNBV Orion Oyj Class B

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

ORION CORPORATION

PRESS RELEASE

4 JULY 2025 at 09.00 EEST          

        

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

Orion will publish Half-Year Financial Report for January–June 2025 on Friday, 18 July 2025 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Friday, 18 July 2025 at 13.30 EEST.

A link to the live webcast is available on Orion's website at . A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link: .

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                 

Contact person:

Tuukka Hirvonen, Head of Investor Relations

tel. +358 10 426 2721 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
04/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Liisa Hurme ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa HurmePosition: Chief Executive ...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Julia Macharey

Orion Corporation: Managers’ transactions – Julia Macharey ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Julia Macharey Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Julia MachareyPosition: Other s...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation: Managers’ transactions – Hao Pan ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Hao PanPosition: Other senior managerIssuer: ...

 PRESS RELEASE

Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan

Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan ORION OYJ        JOHTOHENKILÖIDEN LIIKETOIMET         10.3.2026 KLO 17.00          Orion Oyj: Johtohenkilöiden liiketoimet – Hao Pan Orion Oyj on saanut seuraavan Markkinoiden väärinkäyttöasetuksen (EU) N:o 596/2014 mukaisen ilmoituksen johtohenkilön tai johtohenkilön lähipiirin liiketoimista Orionin osakkeilla tai muilla Orioniin liittyvillä rahoitusvälineillä. Orion Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Hao PanAsema: Muu ylin johtoLiikkeeseenlaskija: Orion OyjLEI: 74370029VAHCXDR7...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation: Managers’ transactions – Outi Vaarala ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET         Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Outi VaaralaPosition: Other senior ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch